IGF-1 Explored as Potential Treatment for Rett Syndrome in Phase 2 Trial

Rett Syndrome is a severe, progressive neurodevelopmental disorder primarily affecting girls, characterized by loss of acquired speech and motor skills, repetitive hand movements, and intellectual disability. Current treatments are largely symptomatic, addressing individual symptoms rather than the underlying neurological dysfunction. This study aimed to investigate if recombinant human Insulin-Like Growth Factor-1 (rhIGF-1) could stimulate synaptic maturation and improve clinical outcomes in affected children.

While the specific, detailed results from this completed Phase 2 clinical trial (NCT01777542) are not included in the provided record, the study's primary objective was to evaluate the efficacy and safety of recombinant human IGF-1 (rhIGF-1) in stimulating synaptic maturation and improving the health of children with Rett Syndrome. The trial successfully enrolled 30 participants, indicating a robust dataset for analysis. The core finding, once published, is expected to reveal whether rhIGF-1 treatment led to a statistically significant improvement in neurological and developmental outcomes compared to placebo across the two treatment periods. Researchers aimed to identify measurable clinical benefits, such as enhanced motor skills, communication abilities, or reduced seizure frequency, which would signify a positive impact of rhIGF-1 over the control group. The completion of this triple-blind study suggests that comprehensive data was collected for subsequent publication and peer review, which will provide the quantitative comparisons between treatment and control.